Using Value-of-Information Methods when the Disease Is Rare and the Treatment Is Expensive—The Example of Hemophilia A

[1]  P. Babyn,et al.  Magnetic resonance imaging and joint outcomes in boys with severe hemophilia A treated with tailored primary prophylaxis in Canada , 2012, Journal of Thrombosis and Haemostasis.

[2]  J. Martin,et al.  Births: final data for 2010. , 2012, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[3]  J. Palmblad,et al.  Treatment of haemophilia A and B and von Willebrand’s disease: summary and conclusions of a systematic review as part of a Swedish health‐technology assessment , 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

[4]  A. Farrugia,et al.  Health technology assessment and haemophilia , 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

[5]  L. Mantovani,et al.  A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study) , 2011, Journal of thrombosis and haemostasis : JTH.

[6]  H. Rossbach.  Review of antihemophilic factor injection for the routine prophylaxis of bleeding episodes and risk of joint damage in severe hemophilia A , 2010, Vascular health and risk management.

[7]  Andrew R Willan,et al.  Optimal sample size determinations from an industry perspective based on the expected value of information , 2008, Clinical trials.

[8]  Deborah M Caldwell,et al.  Research prioritization based on expected value of partial perfect information: a case‐study on interventions to increase uptake of breast cancer screening , 2008 .

[9]  Andrew R Willan,et al.  Time and expected value of sample information wait for no patient. , 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[10]  M. Bullinger,et al.  The economics of haemophilia prophylaxis: governmental and insurer perspectives. PROCEEDINGS OF THE SECOND INTERNATIONAL PROPHYLAXIS STUDY GROUP (IPSG) SYMPOSIUM , 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

[11]  Andrew R Willan,et al.  Clinical decision making and the expected value of information , 2007, Clinical trials.

[12]  Andrew R Willan,et al.  Expected value of information and decision making in HTA. , 2007, Health economics.

[13]  Panos Kanavos,et al.  Assessing the economic challenges posed by orphan drugs , 2007, International Journal of Technology Assessment in Health Care.

[14]  P. Babyn,et al.  Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study , 2006, Journal of thrombosis and haemostasis : JTH.

[15]  S. Donadel-Claeyssens.  Current co‐ordinated activities of the PEDNET (European Paediatric Network for Haemophilia Management) , 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

[16]  D. Hughes,et al.  Drugs for exceptionally rare diseases: do they deserve special status for funding? , 2005, QJM : monthly journal of the Association of Physicians.

[17]  C. McCabe,et al.  Orphan drugs and the NHS: should we value rarity? , 2005, BMJ : British Medical Journal.

[18]  A. Inati,et al.  A comparison between prophylaxis and on demand treatment for severe haemophilia. , 2005, Clinical and laboratory haematology.

[19]  Andrew R Willan,et al.  The value of information and optimal clinical trial design , 2005, Statistics in medicine.

[20]  F. Rosendaal,et al.  Thirty years of hemophilia treatment in the Netherlands, 1972-2001. , 2004, Blood.

[21]  T. Einarson,et al.  Clinical and cost implications of target joints in Canadian boys with severe hemophilia A. , 2004, The Journal of pediatrics.

[22]  A E Ades,et al.  Expected Value of Sample Information Calculations in Medical Decision Modeling , 2004, Medical decision making : an international journal of the Society for Medical Decision Making.

[23]  D. Grobbee,et al.  Prophylactic versus on‐demand treatment strategies for severe haemophilia: a comparison of costs and long‐term outcome , 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

[24]  Hamid Pezeshk,et al.  A Fully Bayesian Approach to Calculating Sample Sizes for Clinical Trials with Binary Responses , 2002 .

[25]  B W Brown,et al.  The sample size for a clinical trial: A Bayesian–decision theoretic approach , 2001, Statistics in medicine.

[26]  Sultan,et al.  Epidemiological survey of the orthopaedic status of severe haemophilia A and B patients in France , 2000, Haemophilia : the official journal of the World Federation of Hemophilia.

[27]  K Claxton,et al.  The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. , 1999, Journal of health economics.

[28]  B. Evatt,et al.  Occurrence of hemophilia in the United States , 1998 .

[29]  J Hornberger,et al.  The cost-benefit of a randomized trial to a health care organization. , 1998, Controlled clinical trials.

[30]  S. Teutsch,et al.  Episodic versus prophylactic infusions for hemophilia A: a cost-effectiveness analysis. , 1996, The Journal of pediatrics.

[31]  J Halpern,et al.  Designing a cost-effective clinical trial. , 1995, Statistics in medicine.

[32]  H. Pettersson,et al.  A longitudinal study of orthopaedic outcomes for severe factor‐VIII‐deficient haemophiliacs , 1994, Journal of internal medicine.

[33]  H. Pettersson,et al.  Twenty‐five years' experience of prophylactic treatment in severe haemophilia A and B , 1992, Journal of internal medicine.

[34]  Thomas K. Hunt,et al.  ON THE TREATMENT OF , 1846 .

[35]  Henry Tulkens,et al.  Evaluating the financial performance of bank branches , 2003, Ann. Oper. Res..

[36]  J. Stockman.  Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia , 2009 .

[37]  B. Evatt,et al.  Occurrence of hemophilia in the United States. The Hemophilia Surveillance System Project Investigators. , 1998, American journal of hematology.